Search Results
Your search for ,Any matches 8114 pages
Showing 7901 - 7950Blacks, Hispanics, Older Americans Not Benefiting Equally From Improvements in Colon Cancer Treatment
While new and better treatments have improved the odds of survival for patients diagnosed with late-stage colorectal cancer, that progress has been largely confined to non-Hispanic whites and Asians and those under age 65, according to a new study published in Cancer Causes and Control. Sineshaw et ...
Aspirin and NSAID Use Reduce Risk of Invasive Epithelial Ovarian Cancer
In a study reported in Journal of the National Cancer Institute, Trabert et al in the Ovarian Cancer Association Consortium found that aspirin use and high-dose nonsteroidal anti-inflammatory drug (NSAID) use were associated with significant reductions in risk for ovarian cancer, with the greatest...
No Difference in Recurrence After 5 Years With or Without Radiotherapy Following Sector Resection in Stage I Breast Cancer
The 20-year follow-up of the Swedish Uppsala/Örebro trial, reported by Wickberg et al in the Journal of Clinical Oncology, shows that improved control of recurrence over 5 years with radiotherapy after sector resection in patients with stage I breast cancer is followed by similar...
Small Panel of FISH Cytogenetic Markers Distinguishes Risk in Medulloblastoma Subgroups
Among the four major molecular subgroups of medulloblastoma, WNT tumors are associated with excellent prognosis, whereas SHH and Group 4 tumors are associated with intermediate and Group 3 tumors with poor prognosis. In a study reported in the Journal of Clinical Oncology, Shih et al identified a...
SSO-ASTRO Consensus Guideline: Margins Wider Than 'No Ink on Tumor' Do Not Further Reduce Risk of Ipsilateral Breast Tumor Recurrence
The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) formed a multidisciplinary expert panel in 2013 to examine the relationship between surgical margin width and ipsilateral breast tumor recurrence and develop guidelines on margins for breast-conserving...
Coordination of Care Improves Patient-Reported Quality of Supportive Care Among Patients With Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, van Ryn et al assessed patient-reported quality of care among patients with colorectal cancer in the Veterans Affairs health-care system. The investigators found significant gaps in patient-centered quality of supportive care, but also found...
Obesity Linked to Poor Survival in Patients With Tongue Cancer
Cancer experts from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College are collaborating to understand the link between obesity and cancer. Most recently, their research has yielded an interesting association: Obesity prior to diagnosis is associated with a fivefold increase...
Newly Created Risk Stratification Database Aids in Predicting Outcomes in Prostate Cancer
The pan-Canadian Prostate Cancer Risk Stratification database was created to report on the patient, tumor, and treatment factors that were predictive of biochemical and clinical outcomes in patients who underwent radiotherapy for prostate cancer. Risk stratification in the management of those with...
Potential Therapeutic Role for Aspirin in the Management of Sporadic Vestibular Schwannoma
In patients with sporadic vestibular schwannoma, aspirin may be of benefit in minimizing tumor growth, according to the results of a retrospective study presented by Kandathil et al in Otology and Neurotology. This finding may eliminate the need for invasive therapy and may complement existing...
ASCO Issues New Recommendations for Family History-Taking in Oncology Setting
When oncologists see a new patient, they should emphasize careful documentation of first- and second-degree cancer family history, according to new recommendations published by the American Society of Clinical Oncology. The recommendations are the first to focus on family history-taking...
Alternative Mechanism of Action Suggested for Vemurafenib in Hairy Cell Leukemia With BRAF V600E Mutation
The finding that the BRAF V600E mutation is present in nearly all cases of hairy cell leukemia has resulted in the use of BRAF inhibitors to treat chemotherapy-resistant disease, with good responses to vemurafenib (Zelboraf) being observed. BRAF inhibition has been thought to result in...
Study Examines Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
In the randomized, phase III CA184-043 trial, ipilimumab (Yervoy) improved progression-free survival and prostate-specific antigen (PSA) response compared with placebo, but failed to improve overall survival significantly in postdocetaxel metastatic castration-resistant prostate cancer....
Bladder Cancer Study Uncovers Potential Drug Targets and Molecular Similarities to Other Cancers
Investigators with The Cancer Genome Atlas Research Network have identified new potential therapeutic targets for urothelial carcinoma of the bladder, a common cancer that causes about 150,000 deaths worldwide each year. The researchers also found molecular similarities to some subtypes of breast,...
Study Reports Success in Targeted Therapy for Lung Adenocarcinoma
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients. The study, published in...
Early Termination Not Unique to Genitourinary Cancer Clinical Trials
An analysis of 7,776 adult cancer clinical trials registered on Clinicaltrials.gov showed that approximately 20% of trials failed to be completed for reasons unrelated to the efficacy or side effects of the intervention. In 2010, a report from the Institute of Medicine entitled “A National...
Angiotensin System Inhibitors Improve Survival in Hypertensive Patients With Metastatic Renal Cell Carcinoma
According to a retrospective study, the use of angiotensin system inhibitors, such as lisinopril, captopril, and losartan, improved the survival of patients with metastatic renal cell carcinoma by 9 months, compared with patients who were not receiving these types of agents. Survival was even...
Enzalutamide Improves Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Enzalutamide (Xtandi) improved survival by 29% in men with chemotherapy-naive metastatic castration-resistant prostate cancer and reduced the risk of radiographic progression by 81%, according to complete results of the randomized, double-blind, placebo-controlled, multinational, phase III PREVAIL...
New Clues May Link Hereditary Cancer Genes to Increased Risk of Cancer From Alcohol
In laboratory experiments conducted on human cell lines at the Johns Hopkins Sidney Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by acetaldehyde, a ...
Melatonin May Potentially Slow Tumor Growth in Estrogen Receptor–Negative Breast Cancers
An early-stage study shows melatonin may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo. The study, published online in the journal PLoS...
PI3K-Delta Inhibitor Idelalisib Produces High Response Rates in Relapsed Indolent Lymphoma
Phosphatidylinositol 3-kinase (PI3K)-delta mediates B-cell receptor signaling and microenvironment support signals that promote the growth and survival of malignant B lymphocytes. In a phase II study reported in The New England Journal of Medicine, Gopal et al found that the PI3K-delta inhibitor...
Adding Idelalisib to Rituximab Improves Progression-Free and Overall Survival in Patients With Difficult-to-Treat, Relapsed CLL
Use of standard chemotherapy is difficult in patients with relapsed chronic lymphocytic leukemia (CLL) who have significant coexisting medical conditions. In a phase III trial reported in The New England Journal of Medicine, Furman et al found that the combination of idelalisib, an oral inhibitor...
Intensive Follow-up Increases Surgical Treatment of Recurrence With Curative Intent in Colorectal Cancer
In a study (FACS trial) reported in JAMA, Primrose et al compared outcomes with intensive follow-up with carcinoembryonic antigen measurement (CEA), computed tomography (CT), both, or minimum follow-up after curative surgery for primary colorectal cancer. Intensive strategies resulted in a...
One-Fifth of Hospitalizations for Patients With Gastrointestinal Cancer Considered Avoidable
In a study reported in the Journal of Clinical Oncology, Brooks et al found that oncology clinicians considered 19% of hospitalizations for patients with gastrointestinal cancers to be avoidable. Study Details In the study, 201 sequential hospital admissions in 154 patients with gastrointestinal...
Long-Term/High-Dose Use of ACE Inhibitors Associated With Reduced Colorectal Cancer Risk in Hypertensive Subjects
Preclinical data suggest a role of angiotensin II in colorectal cancer. In a study reported in the Journal of the National Cancer Institute, Makar et al assessed whether use of angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) treatment for hypertension was...
Maintenance Capecitabine/Bevacizumab Delays Disease Progression in Metastatic Colorectal Cancer and Extends Survival in Subgroups
According to the final results of the phase III CAIRO3 trial by the Dutch Colorectal Cancer Group, maintenance treatment with capecitabine plus bevacizumab (Avastin) significantly delayed progression compared to observation in patients with metastatic colorectal cancer, and in a subset of patients, ...
Adding Chemotherapy to Radiotherapy Does Not Appear to Affect Cognitive Function in Patients With Low-Grade Glioma
The addition of PCV (procarbazine [Matulane], lomustine [CeeNu], vincristine) chemotherapy to radiotherapy improves progression-free survival in patients with grade 2 glioma, but the potential effect of treatment intensification on cognitive function is a concern in this group of patients with good ...
Irinotecan Drug-Eluting Beads Improve Outcomes in Colorectal Cancer Patients With Liver Metastases
Irinotecan drug-eluting beads given simultaneously with FOLFOX (leucovorin, fluorouracil, oxaliplatin) and bevacizumab (Avastin) in patients with unresectable liver metastasis from colorectal cancer improved response rates, increased resectability and prolonged hepatic progression-free survival in...
Preoperative Oral Capecitabine Chemotherapy Is Equivalent to Infusional 5-FU for Rectal Cancer
New findings from a four-arm phase III clinical trial in patients with stage II or stage III rectal cancer indicate that combining preoperative radiation with either capecitabine or fluorouracil (5-FU) results in equivalent outcomes. This study provides strong clinical evidence that using either...
Combination Capecitabine/Temozolomide Appears Highly Effective in Patients With Treatment-Resistant Neuroendocrine Tumors
Interim results from an ongoing phase II clinical trial in patients with various types of advanced neuroendocrine tumors show that a new chemotherapy combination of capecitabine and temozolomide either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after...
Quadrivalent HPV Vaccine Provides Poorer Protection in Women 18 and Older or With Abnormal Cytology
In a study reported in the Journal of Clinical Oncology, Mahmud et al evaluated the effectiveness of the quadrivalent human papillomavirus (HPV) vaccine against cervical dysplasia using population-based individual level data routinely collected in Manitoba. They found that a high proportion of...
Ibrutinib Promising as Initial Therapy for Elderly Patients With CLL in Phase IB/II Trial
Chemoimmunotherapy has produced improved response and survival in young patients with chronic lymphocytic leukemia (CLL), but its use in elderly patients has been limited by myelosuppression and infection. In a phase IB/II study reported in The Lancet Oncology, O’Brien et al assessed the use...
Web-Based Self-Care Support and Communication Coaching Program Reduces Symptom Distress in Cancer Patients
In the ESRA-CII trial reported in the Journal of Clinical Oncology by Berry et al, patient use of a Web-based self-care program featuring tailored education and communication coaching resulted in significantly reduced symptom distress compared with symptom/quality-of-life tracking alone in patients ...
Higher Copayment Associated With Greater Discontinuation of and Nonadherence to Tyrosine Kinase Inhibitor Treatment in CML
The availability of the tyrosine kinase inhibitor imatinib (Gleevec) has dramatically increased survival in chronic myeloid leukemia (CML). Nonadherence to therapy with imatinib and other tyrosine kinase inhibitors is associated with disease progression and treatment resistance. In a study reported ...
Single Fractions of Radiation for Painful Bone Metastases May Be Noninferior to Multiple Fractions
Optimal dose fractionation for radiation therapy of painful bone metastases from multiple primary sites remains undefined. In a phase III noninferiority trial reported in The Lancet Oncology, Chow et al compared 8 Gy in a single fraction vs 20 Gy in multiple fractions in patients with painful bone...
No Difference for Aprepitant vs Dexamethasone for Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer
In a phase III study reported in the Journal of Clinical Oncology, Roila et al compared aprepitant vs dexamethasone in prevention of delayed emesis in breast cancer patients treated with anthracycline/cyclophosphamide who had received palonosetron/aprepitant/dexamethasone prophylaxis for acute...
‘Faster and Deeper Responses’ With Dasatinib vs Imatinib in Chronic-Phase CML Patients
Dasatinib (Sprycel) resulted in “faster and deeper responses” compared to imatinib (Gleevec) among patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML), according to a 3-year follow-up of the randomized phase III DASISION (Dasatinib vs Imatinib Safety In...
Imiquimod 5% Cream Inferior to Surgical Excision in Nodular and Superficial Basal Cell Carcinoma
In a noninferiority trial (SINS) reported in The Lancet Oncology, Bath-Hextall et al compared imiquimod 5% cream vs surgical excision for nodular and superficial basal cell carcinomas. Imiquimod cream was found to be inferior to surgical excision, but it may have a role in treatment of low-risk...
Low-Dose CT Screening May Result in Overdiagnosis of Lung Cancer
In a study reported in JAMA Internal Medicine, Patz et al of the NLST Overdiagnosis Manuscript Writing Team estimated the magnitude of overdiagnosis using low-dose computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). They estimated that more than 18% of...
No Survival Benefit for Tecemotide After Chemoradiotherapy in Stage III NSCLC
In the phase III START trial reported in The Lancet Oncology, Butts et al assessed whether maintenance treatment with the MUC1 antigen–specific immunotherapy tecemotide could prolong overall survival in patients with unresectable stage III non–small cell lung cancer (NSCLC) who had...
EUROCARE-5: Trends in Survival for Childhood Cancers
As reported in The Lancet Oncology by Gatta et al, the population-based EUROCARE-5 study has shown improved survival for all childhood cancers combined in Europe between 1999–2001 and 2005–2007 and persistence of regional survival disparities. Study Details The study involved analysis ...
No Overall Survival Benefit With Addition of Sunitinib to Prednisone in Metastatic Castration-Resistant Prostate Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Michaelson et al assessed the addition of the antiangiogenesis agent sunitinib (Sutent) to prednisone in patients with progressive metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. No...
Protective Effect of Aspirin for Colorectal Cancer Is Associated With rs6983267 T Allele
It has been posited that aspirin treatment may reduce risk for colorectal cancer through inhibition of WNT/cadherin-associated protein β1 (CTNNB1, or β-catenin) signaling. In a study reported in the Journal of the National Cancer Institute, Nan et al investigated the potential role of the ...
Novel BRAF Fusions Identified in 'Pan-Negative' Melanomas
A study by Sosman et al has identified two novel BRAF fusions in melanomas previously considered to be negative for molecular targets. In addition, these “pan-negative” melanomas were found to be sensitive to MEK inhibitors. According to the study, BRAF fusions define a new molecular...
Addition of Bevacizumab Fails to Improve Invasive Disease-Free Survival vs Adjuvant Chemotherapy/Trastuzumab Alone in HER2-Positive Breast Cancer
Bevacizumab (Avastin) failed to extend invasive disease–free survival when added to trastuzumab (Herceptin)-directed adjuvant chemotherapy in patients with HER2-positive breast cancer in the phase III BETH trial. Although not specifically designed to answer this question, BETH also...
ASH 2013: Brentuximab Vedotin Shows Promising Activity in Non-Hodgkin Lymphoma
The antibody-drug conjugate brentuximab vedotin (Adcetris) has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, in a study presented at the American Society of Hematology (ASH) Annual Meeting and Exposition...
No Difference in PFS for Temsirolimus vs Sorafenib as Second-Line Therapy After Sunitinib in Metastatic RCC
In the phase III INTORSECT trial reported in the Journal of Clinical Oncology, Hutson et al compared temsirolimus (Torisel) vs sorafenib (Nexavar) as second-line treatment in patients with metastatic renal cell carcinoma after progression on sunitinib (Sutent). There was no significant difference...
No Difference Between Temsirolimus/Bevacizumab vs Interferon Alfa/Bevacizumab in First-Line Therapy for Metastatic Renal Cell Carcinoma
In the phase III INTORACT trial reported in the Journal of Clinical Oncology, Rini et al compared temsirolimus (Torisel)/bevacizumab (Avastin) vs interferon alfa/bevacizumab in first-line treatment of metastatic renal cell carcinoma. There were no significant differences between the two regimens in ...
Ibrutinib/Rituximab Combination Leads to High Response Rate Among Patients With CLL
Nearly all of the patients with high-risk chronic lymphocytic leukemia (CLL) in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib (Imbruvica) and the antibody rituximab (Rituxan), researchers reported at the 55th American Society of Hematology (ASH) Annual Meeting ...
Reduced Renal Function Observed in Patients Taking Crizotinib for Non‒Small Cell Lung Cancer
Patients receiving crizotinib (Xalkori) for the treatment of anaplastic lymphoma kinase (ALK)-positive non?small cell lung cancer (NSCLC) had reductions in their estimated glomerular filtration rate, according to the findings of a study by Brosnan et al published in the journal Cancer. In the...
Nonsignificant Survival Benefit With Postoperative Radiation Therapy for Head and Neck Cancer at Academic Center vs Other Institutions
In a study reported in JAMA Otolaryngology Head & Neck Surgery, George et al evaluated radiation treatment characteristics and outcomes among head and neck squamous cell carcinoma patients receiving adjuvant external-beam radiation therapy at an academic center vs other institutions....
